David Bomze
Acidosis-mediated increase in IFN-γ-induced PD-L1 expression on cancer cells as an immune escape mechanism in solid tumors.
Knopf P, Stowbur D, Hoffmann S, Hermann N, Maurer A, Bucher V, Poxleitner M, Tako B, Sonanini D, Krishnamachary B, Sinharay S, Fehrenbacher B, Gonzalez-Menendez I, Reckmann F, Bomze D, Flatz L, Kramer D, Schaller M, Forchhammer S, Bhujwalla Z, Quintanilla-Martinez L, Schulze-Osthoff K, Pagel M, Fransen M, Röcken M, Martins A, Pichler B, Ghoreschi K, Kneilling M. Acidosis-mediated increase in IFN-γ-induced PD-L1 expression on cancer cells as an immune escape mechanism in solid tumors. Mol Cancer 2023; 22:207.
Dec 15, 2023Acidosis-mediated increase in IFN-γ-induced PD-L1 expression on cancer cells as an immune escape mechanism in solid tumors.
Dec 15, 2023Mol Cancer 2023; 22:207
Knopf Philipp, Stowbur Dimitri, Hoffmann Sabrina Hl, Hermann Natalie, Maurer Andreas, Bucher Valentina, Poxleitner Marilena, Tako Bredi, Sonanini Dominik, Krishnamachary Balaji, Sinharay Sanhita, Fehrenbacher Birgit, Gonzalez-Menendez Irene, Reckmann Felix, Bomze David, Flatz Lukas, Kramer Daniela, Schaller Martin, Forchhammer Stephan, Bhujwalla Zaver M, Quintanilla-Martinez Leticia, Schulze-Osthoff Klaus, Pagel Mark D, Fransen Marieke F, Röcken Martin, Martins André F, Pichler Bernd, Ghoreschi Kamran, Kneilling Manfred
A replicating LCMV-based vaccine for the treatment of solid tumors.
Purde M, Cupovic J, Palmowski Y, Makky A, Schmidt S, Rochwarger A, Hartmann F, Stemeseder F, Lercher A, Abdou M, Bomze D, Besse L, Berner F, Tüting T, Hölzel M, Bergthaler A, Kochanek S, Ludewig B, Lauterbach H, Orlinger K, Bald T, Schietinger A, Schürch C, Ring S, Flatz L. A replicating LCMV-based vaccine for the treatment of solid tumors. Mol Ther 2023
Dec 5, 2023A replicating LCMV-based vaccine for the treatment of solid tumors.
Dec 5, 2023Mol Ther 2023
Purde Mette-Triin, Cupovic Jovana, Palmowski Yannick A, Makky Ahmad, Schmidt Sarah, Rochwarger Alexander, Hartmann Fabienne, Stemeseder Felix, Lercher Alexander, Abdou Marie-Therese, Bomze David, Besse Lenka, Berner Fiamma, Tüting Thomas, Hölzel Michael, Bergthaler Andreas, Kochanek Stefan, Ludewig Burkhard, Lauterbach Henning, Orlinger Klaus K, Bald Tobias, Schietinger Andrea, Schürch Christian M, Ring Sandra Stephanie, Flatz Lukas
Autoreactive T cells targeting type II pneumocyte antigens in COVID-19 convalescent patients.
Lichtensteiger C, Koblischke M, Berner F, Jochum A, Sinnberg T, Balciunaite B, Purde M, Walter V, Abdou M, Hofmeister K, Kohler P, Vernazza P, Albrich W, Kahlert C, Zoufaly A, Traugott M, Kern L, Pietsch U, Kleger G, Filipovic M, Kneilling M, Cozzio A, Pop O, Bomze D, Bergthaler A, Hasan A, Aberle J, Flatz L. Autoreactive T cells targeting type II pneumocyte antigens in COVID-19 convalescent patients. J Autoimmun 2023; 140:103118.
Oct 10, 2023Autoreactive T cells targeting type II pneumocyte antigens in COVID-19 convalescent patients.
Oct 10, 2023J Autoimmun 2023; 140:103118
Lichtensteiger Christa, Koblischke Maximilian, Berner Fiamma, Jochum Ann-Kristin, Sinnberg Tobias, Balciunaite Beatrice, Purde Mette-Triin, Walter Vincent, Abdou Marie-Therese, Hofmeister Kathrin, Kohler Philipp, Vernazza Pietro L, Albrich Werner, Kahlert Christian, Zoufaly Alexander, Traugott Marianna T, Kern Lukas, Pietsch Urs, Kleger Gian-Reto, Filipovic Miodrag, Kneilling Manfred, Cozzio Antonio, Pop Oltin, Bomze David, Bergthaler Andreas, Hasan Ali, Aberle Judith, Flatz Lukas
Pulmonary Surfactant Proteins Are Inhibited by Immunoglobulin A Autoantibodies in Severe COVID-19.
Sinnberg T, Lichtensteiger C, Ali O, Pop O, Risch L, Brugger S, Velic A, Bomze D, Kohler P, Vernazza P, Albrich W, Kahlert C, Abdou M, Wyss N, Hofmeister K, Niessner H, Zinner C, Gilardi M, Tzankov A, Röcken M, Dulovic A, Shambat S, Ruetalo N, Buehler P, Scheier T, Jochum W, Kern L, Henz S, Schneider T, Kuster G, Lampart M, Siegemund M, Bingisser R, Schindler M, Schneiderhan-Marra N, Kalbacher H, McCoy K, Spengler W, Brutsche M, Macek B, Twerenbold R, Penninger J, Matter M, Flatz L, Jochum A. Pulmonary Surfactant Proteins Are Inhibited by Immunoglobulin A Autoantibodies in Severe COVID-19. Am J Respir Crit Care Med 2023; 207:38-49.
Jan 1, 2023Pulmonary Surfactant Proteins Are Inhibited by Immunoglobulin A Autoantibodies in Severe COVID-19.
Jan 1, 2023Am J Respir Crit Care Med 2023; 207:38-49
Sinnberg Tobias, Lichtensteiger Christa, Ali Omar Hasan, Pop Oltin T, Risch Lorenz, Brugger Silvio D, Velic Ana, Bomze David, Kohler Philipp, Vernazza Pietro, Albrich Werner, Kahlert Christian, Abdou Marie-Therese, Wyss Nina, Hofmeister Kathrin, Niessner Heike, Zinner Carl, Gilardi Mara, Tzankov Alexandar, Röcken Martin, Dulovic Alex, Shambat Srikanth Mairpady, Ruetalo Natalia, Buehler Philipp K, Scheier Thomas C, Jochum Wolfram, Kern Lukas, Henz Samuel, Schneider Tino, Kuster Gabriela M, Lampart Maurin, Siegemund Martin, Bingisser Roland, Schindler Michael, Schneiderhan-Marra Nicole, Kalbacher Hubert, McCoy Kathy D, Spengler Werner, Brutsche Martin H, Macek Boris, Twerenbold Raphael, Penninger Josef M, Matter Matthias S, Flatz Lukas, Jochum Ann-Kristin
Autoreactive napsin A-specific T cells are enriched in lung tumors and inflammatory lung lesions during immune checkpoint blockade.
Berner F, Bomze D, Lichtensteiger C, Walter V, Niederer R, Hasan Ali O, Wyss N, Bauer J, Freudenmann L, Marcu A, Wolfschmitt E, Haen S, Gross T, Abdou M, Diem S, Knöpfli S, Sinnberg T, Hofmeister K, Cheng H, Toma M, Klümper N, Purde M, Pop O, Jochum A, Pascolo S, Jörger M, Früh M, Jochum W, Rammensee H, Läubli H, Hölzel M, Neefjes J, Walz J, Flatz L. Autoreactive napsin A-specific T cells are enriched in lung tumors and inflammatory lung lesions during immune checkpoint blockade. Sci Immunol 2022; 7:eabn9644.
Sep 2, 2022Autoreactive napsin A-specific T cells are enriched in lung tumors and inflammatory lung lesions during immune checkpoint blockade.
Sep 2, 2022Sci Immunol 2022; 7:eabn9644
Berner Fiamma, Bomze David, Lichtensteiger Christa, Walter Vincent, Niederer Rebekka, Hasan Ali Omar, Wyss Nina, Bauer Jens, Freudenmann Lena Katharina, Marcu Ana, Wolfschmitt Eva-Maria, Haen Sebastian, Gross Thorben, Abdou Marie-Therese, Diem Stefan, Knöpfli Stella, Sinnberg Tobias, Hofmeister Kathrin, Cheng Hung-Wei, Toma Marieta, Klümper Niklas, Purde Mette-Triin, Pop Oltin Tiberiu, Jochum Ann-Kristin, Pascolo Steve, Jörger Markus, Früh Martin, Jochum Wolfram, Rammensee Hans-Georg, Läubli Heinz, Hölzel Michael, Neefjes Jacques, Walz Juliane, Flatz Lukas
Keratinocyte differentiation antigen-specific T cells in immune checkpoint inhibitor-treated NSCLC patients are associated with improved survival.
Berner F, Niederer R, Luimstra J, Pop O, Jochum A, Purde M, Hasan Ali O, Bomze D, Bauer J, Freudenmann L, Marcu A, Wolfschmitt E, Haen S, Gross T, Dubbelaar M, Abdou M, Baumgaertner P, Appenzeller C, Cicin-Sain C, Lenz T, Speiser D, Ludewig B, Driessen C, Jörger M, Früh M, Jochum W, Cozzio A, Rammensee H, Walz J, Neefjes J, Flatz L. Keratinocyte differentiation antigen-specific T cells in immune checkpoint inhibitor-treated NSCLC patients are associated with improved survival. Oncoimmunology 2021; 10:2006893.
Nov 27, 2021Keratinocyte differentiation antigen-specific T cells in immune checkpoint inhibitor-treated NSCLC patients are associated with improved survival.
Nov 27, 2021Oncoimmunology 2021; 10:2006893
Berner Fiamma, Niederer Rebekka, Luimstra Jolien J, Pop Oltin Tiberiu, Jochum Ann-Kristin, Purde Mette-Triin, Hasan Ali Omar, Bomze David, Bauer Jens, Freudenmann Lena Katharina, Marcu Ana, Wolfschmitt Eva-Maria, Haen Sebastian, Gross Thorben, Dubbelaar MariLisa, Abdou Marie-Therese, Baumgaertner Petra, Appenzeller Christina, Cicin-Sain Caroline, Lenz Tobias, Speiser Daniel E, Ludewig Burkhard, Driessen Christoph, Jörger Markus, Früh Martin, Jochum Wolfram, Cozzio Antonio, Rammensee Hans-Georg, Walz Juliane, Neefjes Jacques, Flatz Lukas
Erratum to: Severe Coronavirus Disease 2019 (COVID-19) is Associated With Elevated Serum Immunoglobulin (Ig) A and Antiphospholipid IgA Antibodies.
Hasan Ali O, Bomze D, Risch L, Brugger S, Paprotny M, Weber M, Thiel S, Kern L, Albrich W, Kohler P, Kahlert C, Vernazza P, Bühler P, Schüpbach R, Gómez-Mejia A, Popa A, Bergthaler A, Penninger J, Flatz L. Erratum to: Severe Coronavirus Disease 2019 (COVID-19) is Associated With Elevated Serum Immunoglobulin (Ig) A and Antiphospholipid IgA Antibodies. Clin Infect Dis 2021; 73:1746.
Nov 2, 2021Erratum to: Severe Coronavirus Disease 2019 (COVID-19) is Associated With Elevated Serum Immunoglobulin (Ig) A and Antiphospholipid IgA Antibodies.
Nov 2, 2021Clin Infect Dis 2021; 73:1746
Hasan Ali Omar, Bomze David, Risch Lorenz, Brugger Silvio D, Paprotny Matthias, Weber Myriam, Thiel Sarah, Kern Lukas, Albrich Werner, Kohler Philipp, Kahlert Christian, Vernazza Pietro, Bühler Philipp K, Schüpbach Reto A, Gómez-Mejia Alejandro, Popa Alexandra M, Bergthaler Andreas, Penninger Josef M, Flatz Lukas
Severe Coronavirus Disease 2019 (COVID-19) is Associated With Elevated Serum Immunoglobulin (Ig) A and Antiphospholipid IgA Antibodies
Hasan Ali O, Penninger J, Bergthaler A, Popa A, Gómez-Mejia A, Schüpbach R, Bühler P, Vernazza P, Kahlert C, Kohler P, Albrich W, Kern L, Thiel S, Weber M, Paprotny M, Brugger S, Risch L, Bomze D, Flatz L. Severe Coronavirus Disease 2019 (COVID-19) is Associated With Elevated Serum Immunoglobulin (Ig) A and Antiphospholipid IgA Antibodies. Clin Infect Dis 2021; 73:e2869-e2874.
Jan 2, 2021Severe Coronavirus Disease 2019 (COVID-19) is Associated With Elevated Serum Immunoglobulin (Ig) A and Antiphospholipid IgA Antibodies
Jan 2, 2021Clin Infect Dis 2021; 73:e2869-e2874
Hasan Ali Omar, Penninger Josef M, Bergthaler Andreas, Popa Alexandra M, Gómez-Mejia Alejandro, Schüpbach Reto A, Bühler Philipp K, Vernazza Pietro, Kahlert Christian, Kohler Philipp, Albrich Werner, Kern Lukas, Thiel Sarah, Weber Myriam, Paprotny Matthias, Brugger Silvio D, Risch Lorenz, Bomze David, Flatz Lukas
Survival-Inferred Fragility Index of Phase 3 Clinical Trials Evaluating Immune Checkpoint Inhibitors
Bomze D, Asher N, Hasan A, Flatz L, Azoulay D, Markel G, Meirson T. Survival-Inferred Fragility Index of Phase 3 Clinical Trials Evaluating Immune Checkpoint Inhibitors. JAMA Netw Open 2020; 3:e2017675.
Oct 1, 2020Survival-Inferred Fragility Index of Phase 3 Clinical Trials Evaluating Immune Checkpoint Inhibitors
Oct 1, 2020JAMA Netw Open 2020; 3:e2017675
Bomze David, Asher Nethanel, Hasan Ali, Flatz Lukas, Azoulay Daniel, Markel Gal, Meirson Tomer
Ocular Adverse Events Induced by Immune Checkpoint Inhibitors: A Comprehensive Pharmacovigilance Analysis
Bomze D, Meirson T, Hasan A, Goldman A, Flatz L, Habot-Wilner Z. Ocular Adverse Events Induced by Immune Checkpoint Inhibitors: A Comprehensive Pharmacovigilance Analysis. Ocul Immunol Inflamm 2020:1-7.
Aug 4, 2020Ocular Adverse Events Induced by Immune Checkpoint Inhibitors: A Comprehensive Pharmacovigilance Analysis
Aug 4, 2020Ocul Immunol Inflamm 2020:1-7
Bomze David, Meirson Tomer, Hasan Ali, Goldman Adam, Flatz Lukas, Habot-Wilner Zohar
Immune-Related Adverse Events of Immune Checkpoint Inhibitors-From a Clinical to Pathophysiological View-In Reply
Berner F, Bomze D, Flatz L. Immune-Related Adverse Events of Immune Checkpoint Inhibitors-From a Clinical to Pathophysiological View-In Reply. JAMA Oncol 2019
Oct 3, 2019Immune-Related Adverse Events of Immune Checkpoint Inhibitors-From a Clinical to Pathophysiological View-In Reply
Oct 3, 2019JAMA Oncol 2019
Berner Fiamma, Bomze David, Flatz Lukas
BP180-specific IgG is associated with skin adverse events, therapy response, and overall survival in non-small cell lung cancer patients treated with checkpoint inhibitors
Hasan Ali O, Sadik C, Zillikens D, Schmidt E, Jochum W, Mani B, Cozzio A, Braun A, Emtenani S, Hammers C, Abdou M, Diem S, Fässler M, Berner F, Ring S, Bomze D, Flatz L. BP180-specific IgG is associated with skin adverse events, therapy response, and overall survival in non-small cell lung cancer patients treated with checkpoint inhibitors. J Am Acad Dermatol 2019; 82:854-861.
Aug 23, 2019BP180-specific IgG is associated with skin adverse events, therapy response, and overall survival in non-small cell lung cancer patients treated with checkpoint inhibitors
Aug 23, 2019J Am Acad Dermatol 2019; 82:854-861
Hasan Ali Omar, Sadik Christian D, Zillikens Detlef, Schmidt Enno, Jochum Wolfram, Mani Bernhard, Cozzio Antonio, Braun Anne, Emtenani Shirin, Hammers Christoph, Abdou Marie-Therese, Diem Stefan, Fässler Mirjam, Berner Fiamma, Ring Sandra S, Bomze David, Flatz Lukas
Association Between Immune-Related Adverse Events During Anti-PD-1 Therapy and Tumor Mutational Burden
Bomze D, Hasan Ali O, Bate A, Flatz L. Association Between Immune-Related Adverse Events During Anti-PD-1 Therapy and Tumor Mutational Burden. JAMA Oncol 2019
Aug 22, 2019Association Between Immune-Related Adverse Events During Anti-PD-1 Therapy and Tumor Mutational Burden
Aug 22, 2019JAMA Oncol 2019
Bomze David, Hasan Ali Omar, Bate Andrew, Flatz Lukas
Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer
Berner F, Hartmann F, Cheng H, Hönger G, Recher M, Goldman J, Cozzio A, Früh M, Neefjes J, Driessen C, Ludewig B, Hegazy A, Jochum W, Speiser D, Zippelius A, Läubli H, Bomze D, Diem S, Ali O, Fässler M, Ring S, Niederer R, Ackermann C, Baumgaertner P, Pikor N, Cruz C, van de Veen W, Akdis M, Nikolaev S, Flatz L. Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer. JAMA Oncol 2019; 5:1043-1047.
Jul 1, 2019Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer
Jul 1, 2019JAMA Oncol 2019; 5:1043-1047
Berner Fiamma, Hartmann Fabienne, Cheng Hung-Wei, Hönger Gideon, Recher Mike, Goldman Jonathan, Cozzio Antonio, Früh Martin, Neefjes Jacques, Driessen Christoph, Ludewig Burkhard, Hegazy Ahmed N, Jochum Wolfram, Speiser Daniel E, Zippelius Alfred, Läubli Heinz, Bomze David, Diem Stefan, Ali Omar Hasan, Fässler Mirjam, Ring Sandra, Niederer Rebekka, Ackermann Christoph J, Baumgaertner Petra, Pikor Natalia, Cruz Cristina Gil, van de Veen Willem, Akdis Mübeccel, Nikolaev Sergey, Flatz Lukas
Immunoglobulin G and Subclasses as Potential Biomarkers in Metastatic Melanoma Patients Starting Checkpoint Inhibitor Treatment
Diem S, Risch M, Recher M, Risch L, Dummer R, Levesque M, Mangana J, Hillmann D, Niederer R, Berner F, Ali O, Bomze D, Fässler M, Flatz L. Immunoglobulin G and Subclasses as Potential Biomarkers in Metastatic Melanoma Patients Starting Checkpoint Inhibitor Treatment. J Immunother 2019; 42:89-93.
Apr 1, 2019Immunoglobulin G and Subclasses as Potential Biomarkers in Metastatic Melanoma Patients Starting Checkpoint Inhibitor Treatment
Apr 1, 2019J Immunother 2019; 42:89-93
Diem Stefan, Risch Martin, Recher Mike, Risch Lorenz, Dummer Reinhard, Levesque Mitchell P, Mangana Joanna, Hillmann Dorothea, Niederer Rebekka, Berner Fiamma, Ali Omar Hasan, Bomze David, Fässler Mirjam, Flatz Lukas
Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients
Fässler M, Jörger M, Recher M, Risch L, Güsewell S, Risch M, Speiser D, Ludewig B, Levesque M, Dummer R, Siano M, Krolik M, Diem S, Mangana J, Hasan Ali O, Berner F, Bomze D, Ring S, Niederer R, Gil Cruz C, Pérez Shibayama C, Flatz L. Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients. J Immunother Cancer 2019; 7:50.
Feb 20, 2019Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients
Feb 20, 2019J Immunother Cancer 2019; 7:50
Fässler Mirjam, Jörger Markus, Recher Mike, Risch Lorenz, Güsewell Sabine, Risch Martin, Speiser Daniel E, Ludewig Burkhard, Levesque Mitchell P, Dummer Reinhard, Siano Marco, Krolik Michal, Diem Stefan, Mangana Joanna, Hasan Ali Omar, Berner Fiamma, Bomze David, Ring Sandra, Niederer Rebekka, Gil Cruz Cristina, Pérez Shibayama Christian Ivan, Flatz Lukas
Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors
Hasan Ali O, Lenz T, Driessen C, Früh M, Jörger M, Cozzio A, Diem S, Fässler M, Bomze D, Berner F, Flatz L. Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors. Eur J Cancer 2018; 107:8-14.
Dec 7, 2018Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors
Dec 7, 2018Eur J Cancer 2018; 107:8-14
Hasan Ali Omar, Lenz Tobias L, Driessen Christoph, Früh Martin, Jörger Markus, Cozzio Antonio, Diem Stefan, Fässler Mirjam, Bomze David, Berner Fiamma, Flatz Lukas
Tumor infiltrating lymphocytes in lymph node metastases of stage III melanoma correspond to response and survival in nine patients treated with ipilimumab at the time of stage IV disease
Diem S, Hasan Ali O, Ackermann C, Bomze D, Koelzer V, Jochum W, Speiser D, Mertz K, Flatz L. Tumor infiltrating lymphocytes in lymph node metastases of stage III melanoma correspond to response and survival in nine patients treated with ipilimumab at the time of stage IV disease. Cancer Immunol Immunother 2017; 67:39-45.
Sep 11, 2017Tumor infiltrating lymphocytes in lymph node metastases of stage III melanoma correspond to response and survival in nine patients treated with ipilimumab at the time of stage IV disease
Sep 11, 2017Cancer Immunol Immunother 2017; 67:39-45
Diem Stefan, Hasan Ali Omar, Ackermann Christoph J, Bomze David, Koelzer Viktor H, Jochum Wolfram, Speiser Daniel E, Mertz Kirsten D, Flatz Lukas
Topological Small-World Organization of the Fibroblastic Reticular Cell Network Determines Lymph Node Functionality
Novkovic M, Turley S, Bocharov G, Stein J, Scandella E, Cremasco V, Bomze D, Abe J, Cupovic J, Onder L, Ludewig B. Topological Small-World Organization of the Fibroblastic Reticular Cell Network Determines Lymph Node Functionality. PLoS Biol 2016; 14:e1002515.
Jul 14, 2016Topological Small-World Organization of the Fibroblastic Reticular Cell Network Determines Lymph Node Functionality
Jul 14, 2016PLoS Biol 2016; 14:e1002515
Novkovic Mario, Turley Shannon J, Bocharov Gennady, Stein Jens V, Scandella Elke, Cremasco Viviana, Bomze David, Abe Jun, Cupovic Jovana, Onder Lucas, Ludewig Burkhard
Alternative NF-κB signaling regulates mTEC differentiation from podoplanin-expressing presursors in the cortico-medullary junction
Onder L, Waisman A, Becher B, Ledermann B, Mair F, Maier R, Bomze D, Novkovic M, Caviezel-Firner S, Cheng H, Chai Q, Scandella E, Nindl V, Ludewig B. Alternative NF-κB signaling regulates mTEC differentiation from podoplanin-expressing presursors in the cortico-medullary junction. Eur J Immunol 2015
May 14, 2015Alternative NF-κB signaling regulates mTEC differentiation from podoplanin-expressing presursors in the cortico-medullary junction
May 14, 2015Eur J Immunol 2015
Onder Lucas, Waisman Ari, Becher Burkhard, Ledermann Birgit, Mair Florian, Maier Reinhard, Bomze David, Novkovic Mario, Caviezel-Firner Sonja, Cheng Hung-Wei, Chai Qian, Scandella Elke, Nindl Veronika, Ludewig Burkhard